SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as traders react to a significant workforce reduction aimed at streamlining operations amidst record-breaking trading volumes across its equity, options, and prediction market platforms. The community is actively debating whether this efficiency play signals long-term growth or cooling momentum, while many are focused on key price levels and bullish sentiment regarding the company's broader push into AI-driven trading tools and international expansion.

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Multicloud Services and Apps & Cross Platform. The Multicloud Services segment includes public and private cloud managed services offerings, as well as professional services related to designing and building multicloud solutions and cloud-native applications. The Apps & Cross Platform segment includes managed applications, managed security and data services, as well as professional services related to designing and implementing application, security and data services. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology Inc. is seeing significant market interest as investors react to a confirmed partnership with AMD for AI compute infrastructure and aggressive workforce realignment strategies aimed at driving future growth. Community sentiment is mixed but largely bullish, with many focusing on the stock's potential for institutional accumulation and its pivot toward high-margin AI data center services.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing heightened volatility and intense social media debate as investors weigh the impact of acquisition rumors, potential M&A strategy shifts, and recent downward price action against its underlying subscriber growth. The community remains deeply divided, with many expressing frustration over management's capital allocation and content direction while others argue the stock is fundamentally undervalued at current levels.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging as investors react to its upcoming inclusion in the Nasdaq-100 and the completed acquisition of Eigen AI, which strengthens its inference optimization capabilities. The community is actively debating the stock's long-term potential as a hyperscaler-style AI infrastructure winner versus concerns regarding its debt load and broader sector leverage.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is surging as investors cheer positive data for the subcutaneous version of its flagship MS treatment, which supports a streamlined dosing schedule and bolsters long-term growth prospects. The community is buzzing with speculation that the company's improved clinical profile and expanded market opportunity make it a prime candidate for a significant buyout.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is experiencing a sharp rebound as investors rotate back into the stock, fueled by optimism over its subscription-based monetization strategy and the potential for a reversal in its recent downward trend. The community remains deeply divided, with many traders debating whether the recovery is a sustainable shift or just another temporary bounce, while closely monitoring key resistance levels near $600.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors position for significant upcoming catalysts, including Phase 3 data readouts and potential M&A interest. The community is actively debating the company's clinical pipeline milestones and the strategic implications of management's participation at major upcoming investor conferences.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is trending as the community debates a sharp stock decline following FDA feedback that dampened hopes for an immediate accelerated approval path for its Huntington's disease gene therapy. Investors are actively discussing the potential for long-term recovery, the ethics of the FDA's request for placebo-controlled studies, and the company's significant cash position relative to its current market valuation.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is currently a focal point for investors due to recent government contract wins and the integration of its SwarmOS software with drone platforms, which is fueling high-conviction debate about its potential as a defense technology leader. The community is actively discussing the stock's significant short interest and volatility, with long-term investors highlighting its growth in defense autonomy while others express skepticism regarding the company's path to consistent revenue and share dilution.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is under intense scrutiny as investors grapple with slowing enterprise IT spending and fears that generative AI could disrupt its traditional consulting model. While the company faces pressure from recent institutional downgrades, market attention is focused on whether its upcoming earnings can signal a turnaround by proving that AI implementation, rather than just automation, is driving sustainable revenue growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Technological Innovations to Wage War Against Some of Medicine's Toughest Diseases

The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. $NTHI, $QURE, $ICCM, $CLPT, $ELTX, $AZTR

QURE Stock Surges Over 70% After FDA Softens Stance On Huntington’s Disease Gene Therapy

Equity

uniQure said that the U.S. Food and Drug Administration is willing to consider three years of data as the primary basis for a biologics license application of AMT-130.

Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message

Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message...

REPL, QURE Stocks Rise Amid Makary’s Reported Resignation As FDA Chief

The New York Times reported that Makary’s departure was driven in large part by his strong opposition to the administration’s decision to authorize fruit-flavored e-cigarettes.


REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary 

The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.


uniQure Q1 Earnings Call Highlights

uniQure (NASDAQ:QURE) executives outlined progress and upcoming regulatory milestones for lead Huntington's disease gene therapy candidate AMT-130 during the company's first-quarter 2026 earnings call, while also providing updates across its epilepsy and Fabry programs and reviewing quarterly financ...

uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results

uniQure (NASDAQ:QURE - Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analysts...

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +2.86% and -48.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

uniQure (NASDAQ:QURE) Shares Up 6.3% - Still a Buy?

uniQure (NASDAQ:QURE) Stock Price Up 6.3% - Time to Buy...

Jennison Associates LLC Boosts Stake in uniQure N.V. $QURE

Jennison Associates LLC raised its position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) by 37.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,371,190 shares of the biotechnology company's s...

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

The stock surged over 70% after the FDA unexpectedly green-lit an accelerated approval pathway for its Huntington's gene therapy, AMT-130.

Traders are closely monitoring heavy short interest of over 11 million shares as the aggressive price action forces rapid covering.

The major regulatory win for gene therapy is creating massive spillover momentum in related biotech names like CLPT, SRPT, and IBRX.

Following the positive FDA surprise and upgraded analyst outlooks, investors are speculating on aggressive upside targets reaching toward $80-$100.

QUREuniQure NV

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QURE News